Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310069 | 0.87 | CACNA1H (0.32) | — | |
| SCHEMBL2389245 | 0.86 | CNR2 (0.34) | MDM4MDM2 | |
| SCHEMBL2389246 | 0.86 | CNR2 (0.34) | MDM4MDM2 | |
| SCHEMBL2389242 | 0.77 | S1PR1 (0.34) | MDM4MDM2 | |
| SCHEMBL2394168 | 0.73 | CNR2 (0.35) | — | |
| SCHEMBL2394172 | 0.73 | CNR2 (0.35) | — | |
| SCHEMBL27893944 | 0.72 | CNR2 (0.32) | — | |
| SCHEMBL2395843 | 0.72 | SLC6A3 (0.40) | — | |
| SCHEMBL2395841 | 0.72 | SLC6A3 (0.40) | — | |
| SCHEMBL2393190 | 0.71 | MDM2 (0.34) | MDM4MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | NOVARTIS AG (CH) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129871-A1 | Crystalline form of an inhibitor of MDM2/4 and p53 interaction | MDM4, TP53, TP53BP1 | MDM4 1/4885MDM2 4/4885HSD11B1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.